Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01068470

Acronym

LAK

Enrollment

Registered

2010-02-15

Start date

2009-11-30

Completion date

2012-03-31

Last updated

2014-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Cancer, Melanoma

Keywords

Interleukin-2, Melanoma, Kidney Cancer, Lymphokine Activated Killer cells

Brief summary

Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.

Detailed description

Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic dehydrogenase release from lysed cells.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must be undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center * Patients must sign and give written informed consent in accordance with institutional and federal guidelines

Exclusion criteria

* Patients not undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center

Design outcomes

Primary

Measure	Time frame
LAK cytotoxicity	4 months

Countries

United States

Outcome results